PLEASANTON, Calif., Oct. 31, 2013 (GLOBE NEWSWIRE) -- ZELTIQ® (Nasdaq:ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that Mark Foley, President and Chief Executive Officer and Patrick F. Williams, Senior Vice President and Chief Financial Officer, are scheduled to present at the Canaccord Genuity Medical Technology and Diagnostics Forum at The Westin Grand Central in New York City.
Event: Canaccord Genuity Medical Technology and Diagnostics Forum
Date: November 14, 2013
Time: 10:00 a.m. ET
An audio webcast of the Company's presentation will be available by visiting the investor relations section of ZELTIQ's web site at www.coolsculpting.com. A replay of the presentation will be available for 90 days.
About ZELTIQ® Aesthetics, Inc.
ZELTIQ is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting System, is designed to selectively reduce stubborn fat that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer.
CONTACT: Investor Relations: Patrick F. Williams ZELTIQ, Senior Vice President and CFO 925-474-2500 Nick Laudico / Rada Milenovici The Ruth Group 646-536-7030 / 646-536-7011 email@example.com
Source:ZELTIQ Aesthetics, Inc.